Locally Advanced Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction Staging

Discussion on Surgically Resectable vs Unresectable Tumors

Factors to Consider When Choosing Between Concurrent or Sequential CRT

Concurrent CRT Increases OS Benefit

Deciding Which Chemotherapy to Use

Introduction Checkpoint Inhibitors

Rationale for Immunotherapy After CRT

PACIFIC Trial Study Design

PACIFIC Trial PFS in the ITT Population

PACIFIC Trial Subgroup Analysis of Prognostic Factors for PFS

Best Practices for Scanning After CRT

PACIFIC Trial Rationale for Performing Scan Immediately After CRT

PACIFIC Trial Metastases in the ITT Population

Limitations of the PACIFIC Trial

Assessments That Should Be Performed Before CRT

Key Takeaways From PACIFIC Trial

imAEs

Monitoring for imAEs

PACIFIC Trial Safety Profile

Managing Pneumonitis in Patients Receiving Durvalumab After CRT

Treatment Approach to Surgically Resectable vs Surgically Unresectable Patient Population

Phase 2 Study of Pembrolizumab After LAT in Patients With Oligometastatic NSCLC

Conclusions and Ongoing Studies

Abbreviations

Abbreviations (cont)

Abbreviations (cont)